PRODUCTDRUG CLASSINDICATIONTARGETPROGRESSPARTNERPRE-CLINICALPHASE IPHASE II/IIIMAA/BLAEG12014*(EIRGASUN®  /  HERWENDA®) Trastuzumab biosimilarMonoclonal AntibodyHER2+ Breast Cancer (BC)HER 2EG1206APertuzumab biosimilarMonoclonal AntibodyHER2+ BCHER 2*Phase III WaivedEG12043 (TSY110)Kadcyla biosimilarAntibody Drug Conjugate (ADC)HER2+ BCHER 2EG13084Phesgo (SC formulation)Monoclonal AntibodyHER2+ BCHER 2-EG12112Atezolizumab biosimilarMonoclonal AntibodySolid TumorsPD-L1-EG12164Daratumumab biosimilarMonoclonal AntibodyMyelomaCD38-EG7412FHyaluronidase (rHuPH20)EnzymeN/AHigh-dose mAb forms.-EG12170Trastuzumab-deruxtecan biosimilarAntibody Drug ConjugateHER2+ BCHER 2  #winho-pipeline-section .winho-table-responsive { width: 100%; overflow-x: auto; -webkit-overflow-scrolling: touch;}#winho-pipeline-section table { min-width: 1000px; width: 100%; margin-bottom: 0;}#winho-pipeline-section table th,#winho-pipeline-section table td { vertical-align: middle; word-break: normal; overflow-wrap: normal;}#winho-pipeline-section table thead th:nth-child(1),#winho-pipeline-section table tbody td:nth-child(1) { min-width: 160px; }#winho-pipeline-section table thead th:nth-child(2),#winho-pipeline-section table tbody td:nth-child(2) { min-width: 130px; }#winho-pipeline-section table thead th:nth-child(3),#winho-pipeline-section table tbody td:nth-child(3) { min-width: 120px; }#winho-pipeline-section table thead th:nth-child(4),#winho-pipeline-section table tbody td:nth-child(4) { min-width: 90px; }#winho-pipeline-section .ex-progress-bar { text-align: left;}#winho-pipeline-section table img { max-width: 100%;}#winho-pipeline-section .ex-progress-bar img { min-height: 30px;}